1: (ROOT (S (NP (NP (NNP HCQ)) (ADJP (JJ Effective) (PP (IN For) (NP (CD COVI-19)))) (PP (IN In) (NP (NP (JJ Small) (NNS TrialPatients)) (PP (IN in) (NP (NNP China))) (PP (IN with) (NP (NP (CD COVI-19)) (VP (VBN treated) (PP (IN with) (NP (NNP HC) (SYM /) (NNP hydroxychloroquine))))))))) (VP (VBD were) (VP (VBN observed) (S (VP (TO to) (VP (VB have) (NP (NP (NP (DT a) (JJR shorter) (NN time)) (PP (IN to) (NP (JJ clinical) (NN recovery)))) (CONJP (RB as) (RB well) (IN as)) (NP (VBN improved) (NN pneumonia))) (PP (IN in) (NP (DT a) (VBN randomized) (NN trial)))))))) (. .)))
2: (ROOT (S (NP (NNP HCQ)) (VP (VBZ is) (NP (NP (DT an) (NN antimalarial)) (SBAR (WHNP (WDT that)) (S (VP (VBZ is) (ADVP (RB also)) (VP (VBN used) (S (VP (TO to) (VP (VB treat) (NP (NP (JJ autoimmune) (NNS diseases)) (PP (JJ such) (IN as) (NP (NN lupus))))))))))))) (. .)))
3: (ROOT (S (NP (NP (DT Those)) (SBAR (WHNP (WDT that)) (S (VP (VBD received) (NP (NN hydroxychloroquine)) (PP (IN with) (NP (JJ standard) (NN treatment))))))) (VP (VBD were) (VP (VBN observed) (TO to) (VP (VB have) (VP (VBD had) (NP (NP (NP (NP (DT a) (ADJP (RB significantly) (JJR shorter)) (NN time)) (PP (IN to) (NP (NML (NN body) (NN temperature)) (NN recovery))) (PP (IN of) (NP (QP (RB about) (CD one)) (NN day)))) (CONJP (RB as) (RB well) (IN as)) (NP (NP (NP (DT a) (ADJP (RB significantly) (VBN reduced)) (NN time)) (PP (IN to) (NP (NN cough) (NN remission))) (PP (IN of) (NP (QP (RB about) (DT a)) (NN day)))) (PP (VBN compared) (PP (IN to) (NP (NP (NNS patients)) (VP (VBG receiving) (NP (RB only) (DT the) (JJ standard) (NN treatment)))))))) (PP (VBG according) (PP (IN to) (NP (NP (NNS reports)) (PP (IN from) (NP (NP (NNP Zhan) (NNP Zhang)) (, ,) (NP (NP (NNP MD)) (PP (IN of) (NP (NNP Wuhan) (NNP University)))))))))))))) (. .)))
4: (ROOT (S (NP (NP (DT A) (JJR larger) (NN proportion)) (PP (IN of) (NP (NP (NNS patients)) (PP (IN in) (NP (NP (DT the) (NN group)) (VP (VBG receiving) (NP (DT the) (NN hydroxychloroquine)) (PP (IN with) (NP (JJ standard) (NN treatment))))))))) (VP (VBD had) (VP (VBN improved) (NP (NN pneumonia)) (PP (VBN compared) (PP (IN to) (NP (NP (DT those)) (PP (IN in) (NP (DT the) (NN control) (NN group)))))) (, ,) (PP (VBG according) (PP (IN to) (NP (NP (DT a) (NN manuscript)) (VP (VBN posted) (PP (IN on) (NP (DT the) (NNP medRxiv) (NN preprint) (NN server))))))))) (. .)))
5: (ROOT (S (S (S (NP (NN Hydroxychloroquine) (CC and) (NN chloroquine)) (VP (VBP have) (VP (VBN been) (VP (VBG getting) (NP (JJ much) (NN attention)) (ADVP (RB lately)))))) (, ,) (CC and) (S (NP (DT the) (NNP FDA)) (VP (VBZ is) (VP (VBG looking) (PP (IN into) (S (VP (VBG conducting) (NP (NP (JJ randomized) (NNS trials)) (PP (IN against) (NP (CD COVI-19))))))))))) (, ,) (NP (NP (PRP it))) (VP (VBZ is) (ADJP (JJ worth) (NP (VBG noting))) (SBAR (IN that) (S (S (NP (DT some) (NN hospital)) (VP (VBP have) (VP (VBN begun) (S (VP (VBG using) (NP (NP (DT a) (NN cocktail)) (PP (IN of) (NP (NN azithromycin) (CC and) (NN hydroxychloroquine)))) (PP (TO to) (NP (ADJP (RB desperately) (JJ ill)) (NNS patients))) (PP (IN on) (NP (DT a) (NML (JJ compassionate) (NN care)) (NN basis)))))))) (, ,) (CC and) (S (NP (EX there)) (VP (VBP are) (NP (NP (JJ unconfirmed) (NNS reports)) (PP (IN of) (S (NP (DT some)) (ADVP (RB even)) (VP (VBG using) (NP (NML (PP (IN off) (NP (NN label)))) (NN use)) (PP (IN of) (NP (DT these) (NNS agents)))))))))))) (. .)))
6: (ROOT (S (PP (IN Due) (IN to) (NP (DT the) (NN attention))) (NP (DT the) (NNP CDC)) (VP (VBZ has) (VP (VBN issued) (NP (NP (DT a) (NN warning)) (PP (IN to) (NP (NNS people))) (PP (IN against) (S (VP (VBG taking) (NP (NN medication) (SYM /) (NNS remedies)))))) (SBAR (WHNP (WDT that)) (S (NP (PRP they)) (VP (VBP do) (`` ') (RB t) (VP (VP (VB understand)) (SBAR (IN as) (S (NP (CD one) (JJ unfortunate) (NN person)) (VP (VP (VBD died) (PP (IN from) (S (VP (VBG ingesting) (NP (NP (NN chloroquine) (NN phosphate)) (SBAR (WHNP (WDT which)) (S (VP (VBZ is) (VP (VBN used) (S (VP (TO to) (VP (VB clean) (NP (NN fish) (NNS tanks)))))))))))))) (, ,) (CC but) (VP (VBD thought) (SBAR (S (NP (PRP it)) (VP (VBD was) (NP (NP (DT the) (NN product)) (VP (VBG getting) (NP (PDT all) (DT the) (NN attention)) (PP (IN in) (NP (DT the) (NNS media)))))))))))))))))) (. .)))
7: (ROOT (S (NP (NP (JJ Previous) (NNS trials)) (VP (VBG exploring) (NP (NP (DT the) (NML (PP (IN in) (FW vivo))) (NN activity)) (PP (IN of) (NP (NNP HCQ)))))) (VP (VBD had) (VP (VBN found) (NP (NP (DT no) (NN benefit)) (PP (IN in) (NP (NP (JJ clinical) (NNS measures)) (CC or) (NP (JJ viral) (NN clearance)))) (PP (VBN compared) (PP (IN to) (NP (JJ standard) (NN care))))))) (. .)))
8: (ROOT (S (NP (DT The) (NN drug)) (VP (VBZ continues) (S (VP (TO to) (VP (VB be) (VP (VBN tested) (PP (IN in) (NP (NP (NNS trials)) (PP (VBG including) (NP (NP (DT this) (VBN randomized) (NN trial)) (VP (VBG involving) (NP (NP (CD 62) (JJ hospitalized) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (VP (VP (VBN tested)) (CC and) (VP (VBN confirmed) (S (VP (TO to) (VP (VB be) (VP (VBN infected) (PP (IN with) (NP (CD COVI-19))))))))))))))))))))))) (. .)))
9: (ROOT (S (S (NP (DT All) (NNS patients)) (VP (VBD received) (NP (NP (JJ standard) (NN care)) (PP (VBG including) (NP (NP (NN oxygen) (NN therapy)) (, ,) (NP (JJ antiviral) (NNS agents)) (, ,) (NP (JJ antibacterial) (NNS agents)) (, ,) (CC and) (NP (NN immunoglobulin) (NN wit) (SYM /) (IN without) (NP (NNS corticosteroids)))))))) (: :) (S (NP (NP (DT those)) (PP (IN in) (NP (DT the) (NN intervention) (NNS groups)))) (ADVP (RB also)) (VP (VBD received) (NP (NP (NML (CD 400) (NNS mg)) (NNS tablets)) (PP (IN of) (NP (JJ oral) (NN hydroxychloroquine) (NN sulfate))) (PP (IN per) (NP (NN day))) (PP (IN on) (NP (NNS days) (SYM -5)))))) (. .)))
10: (ROOT (S (NP (JJ Primary) (NN endpoint)) (VP (VBD was) (NP (NP (NP (NN time)) (PP (IN to) (NP (JJ clinical) (NN recovery)))) (SBAR (WHNP (WDT which)) (S (VP (VBD was) (VP (VBN defined) (PP (IN as) (S (VP (VBG being) (NP (NP (NP (DT the) (`` `) (NN return)) (PP (IN to) (NP (NP (NN body) (NN temperature)) (CC and) (NP (NN cough) (NN relief))))) (, ,) (VP (VBN maintained) (PP (IN for) (NP (QP (JJR more) (IN than) (CD 72))))))))))))))) (. .) ('' ')))
11: (ROOT (S (S (NP (DT The) (JJ mean) (NN patient) (NN age)) (VP (VBD was) (NP (CD 45)))) (CC and) (S (NP (NP (QP (RB almost) (NN half)))) (VBD were) (NP (NNS men))) (, ,) (PP (IN with) (NP (NP (DT no) (JJ significant) (NNS differences)) (PP (PP (IN in) (NP (DT the) (NML (NN age) (CC and) (NN sex)) (NN distribution))) (PP (IN between) (NP (DT the) (NNS groups)))))) (PP (VBG according) (PP (IN to) (NP (DT the) (NNS authors)))) (. .)))
12: (ROOT (S (S (NP (NP (CD 4)) (PP (IN of) (NP (NP (DT the) (CD 62) (NNS patients)) (PP (IN in) (NP (DT the) (NN control) (NN group)))))) (VP (VBD were) (VP (VBN noted) (S (VP (TO to) (VP (VB progress) (PP (IN to) (NP (JJ severe) (NN illness))))))))) (, ,) (CC and) (S (NP (CD 2) (NNS patients)) (VP (VBD reported) (S (VP (VBG having) (NP (JJ mild) (JJ adverse) (NNS reactions)) (PP (IN in) (NP (DT the) (NNP HCQ) (NN group))))))) (. .)))
13: (ROOT (S (S (NP (NP (DT Those)) (PP (IN in) (NP (DT the) (NNP HCQ) (NN group)))) (VP (VBD had) (NP (NP (DT a) (ADJP (NP (CD one) (NN day)) (JJR shorter)) (NN time)) (PP (IN to) (NP (NML (NN body) (NN temperature)) (NN recovery)))))) (CC and) (S (NP (JJ similar) (NNS results)) (VP (VBD were) (VP (VBN seen) (PP (IN for) (NP (NP (NN time)) (SBAR (S (VP (TO to) (NP (NN cough) (NN remission)))))))))) (. .)))
14: (ROOT (S (NP (NN Retinopathy)) (VP (VBZ is) (NP (NP (NP (DT a) (JJ known) (JJ side) (NN effect)) (PP (IN from) (NP (NP (NML (JJ long) (NN term)) (NN therapy)) (PP (IN with) (NP (NN hydroxychloroquine)))))) (SBAR (WHNP (WDT which)) (S (VP (MD can) (ADVP (RB often)) (VP (VB be) (VP (VBN seen) (PP (IN in) (NP (NP (NN lupus) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (MD may) (VP (VB remain) (PP (IN on) (NP (DT the) (NN drug))) (PP (IN for) (NP (NNS years)))))))))))))))) (. .)))
15: (ROOT (S (NP (NP (DT Those)) (PP (IN on) (NP (NML (JJ long) (NN term)) (NN use)))) (VP (MD may) (ADVP (RB also)) (VP (VB experience) (NP (NP (NNS arrhythmias)) (, ,) (NP (JJ gastrointestinal) (NNS reactions)) (, ,) (NP (NNS cramps)) (, ,) (CC and) (NP (NN liver) (NN dysfunction))))) (. .)))
16: (ROOT (S (S (NP (NP (NNS Patients)) (PP (IN on) (NP (NN hydroxychloroquine) (NN therapy)))) (VP (MD should) (VP (VB be) (VP (VBN monitored) (PP (IN for) (NP (JJ adverse) (NNS reactions))))))) (, ,) (CC but) (S (PP (VBG according) (PP (IN to) (NP (NNP Zhang) (CC and) (NNS colleagues)))) (NP (NP (DT the) (`` `) (NML (NN shor) (HYPH -) (NN term)) (NN application)) (PP (IN of) (NP (NNP HCQ)))) (VP (VBZ is) (ADJP (RB relatively) (JJ safe)))) (. .) ('' ')))
17: (ROOT (S (NP (DT The) (NNS authors)) (VP (VBD concluded) (SBAR (IN that) (`` `) (S (VP (VBG considering) (SBAR (IN that) (S (NP (EX there)) (VP (VBZ is) (NP (DT no) (JJR better) (NN option)) (PP (IN at) (ADJP (JJ present)))))))) (, ,) (NP (NP (PRP it))) (VP (VBZ is) (NP (DT a) (JJ promising) (NN practice)) (S (VP (TO to) (VP (VB apply) (NP (NNP HCQ)) (PP (IN to) (NP (CD COVI-19))) (PP (IN under) (NP (JJ reasonable) (NN management)))))) (, ,) ('' ') (SBAR (IN while) (S (ADVP (RB also)) (VP (VBG acknowledging) (SBAR (S (NP (EX there)) (VP (VBZ is) (ADVP (RB still)) (NP (NP (DT a) (NN need)) (PP (IN for) (NP (NP (NP (NML (JJ large) (NN scale)) (JJ clinical) (NNS trials)) (CC and) (NP (JJ other) (NN research))) (SBAR (S (VP (VP (TO to) (VP (VB clarify) (NP (DT the) (NN treatment) (NNS mechanisms)))) (CC and) (VP (TO to) (VP (VB optimize) (NP (DT the) (NN treatment) (NN plan))))))))))))))))))) (. .)))
18: (ROOT (S (NP (DT This) (NN study)) (VP (VBD was) (VP (VBN supported) (PP (IN by) (NP (NP (NP (DT the) (NNP Epidemiological) (NNP Study)) (PP (IN of) (NP (NP (HYPH COVI-19) (NNP Pneumonia)) (PP (IN to) (NP (NNP Science) (CC and) (NNP Technology)))))) (, ,) (NP (NP (NNP Department)) (PP (IN of) (NP (NNP Hubei) (NNP Province)))))))) (. .)))
